SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending as the cannabis sector is gaining momentum amid discussions of potential federal policy changes, including reclassification of marijuana. The community is closely watching for announcements from the Trump administration and the Supreme Court, anticipating a short squeeze. Positive news around Redecan's new product launch is also contributing to the bullish sentiment.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as discussions around cannabis reform and rescheduling heat up, with community members highlighting the coin's connection to cannabis culture. Many allude to the coin's long-term vision and organic community growth, drawing comparisons to Bitcoin. The community emphasizes a culture-driven approach, with some seeing a potential tie-in with cannabis industry developments.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors digest the potential impacts of both competitor Broadcom's earnings and news regarding AI chip exports to China. The community is actively discussing AMD's valuation, potential catalysts, and technical indicators for possible breakouts, with some focusing on long-term growth prospects. Some traders are also pointing to the potential of an island reversal.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending following a Q3 earnings beat, raised full-year guidance, and a significant buyback announcement, coupled with news of CEO succession plans. Community members are weighing in on the company's growth trajectory, potential analyst upgrades, and the impact of international sales, especially in China. Some traders are noting the potential for a short squeeze, while others are discussing the impact of leadership changes.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss the potential of Pemvidutide, particularly after positive feedback on PathAI's analysis. The community is weighing the possibilities of a partnership or buyout, considering the drug's promise in treating obesity, liver, and cardiometabolic diseases. Bullish and bearish investors are debating trial data and potential outcomes.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as investors debate its future amidst discussions around its valuation and potential for growth compared to competitors like BABA and PDD. Community members are actively discussing whether the stock is undervalued, with some pointing to its cash reserves and potential for buybacks, while others express concerns about its underperformance and the impact of broader economic trends in China. Speculation around potential acquisitions and strategic shifts, such as expanding into new markets, are also being closely watched.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco's stock is trending as investors evaluate recent earnings, which beat expectations but saw a slow reaction in the post-market, alongside discussions on the stock's high PE ratio. Community members are actively debating the company's growth strategy, including expansion plans and digital integration, as well as the potential for a stock split or special dividend to attract more investors. Costco's solid financial performance and consistent execution are also being weighed against concerns about its valuation relative to industry peers.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss the potential for a buyout or strategic partnership, fueled by promising data in lung, prostate, and pancreatic cancers. Community talking points center on the company being significantly undervalued with a large short interest, positioning it for a potential squeeze. LOAD!

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending amidst high volatility and a wide range of community perspectives, with some traders citing the stock's low float and potential for a squeeze. Discussions revolve around a recent surge in price followed by a sharp decline, leaving investors debating whether to hold for a potential rebound or exit. The conversation also includes speculation about upcoming announcements, and potential catalysts.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is experiencing volatility following earnings, initially jumping on strong AI chip demand and guidance, but then declining due to profit-taking and concerns about non-AI revenue. The community is actively debating whether the pullback is a buying opportunity or a sign of an overvalued stock, with some pointing to potential gross margin compression and dependence on OpenAI revenue as causes for concern. Despite the mixed sentiment, underlying AI demand remains a key talking point, with analysts weighing in on future target prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Thursday 12/11 Insider Buying Report: ADVM, ALTG

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At...

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition PR Newswire...

Insider Buying: Adverum Biotechnologies (NASDAQ:ADVM) CEO Purchases 11,085 Shares of Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer purchased 11,085 shares of the company's stock in a transaction that occurred on Friday, December 5th. The shares...

Adverum Biotechnologies (NASDAQ:ADVM) COO Purchases $211,000.00 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) COO Peter Soparkar bought 50,000 shares of the company's stock in a transaction dated Friday, December 5th. The stock was bought at an...

Adverum Biotechnologies (NASDAQ:ADVM) CEO Buys $47,000.40 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer purchased 11,085 shares of the firm's stock in a transaction that occurred on Friday, December 5th. The stock was...

Laurent Fischer Acquires 117,614 Shares of Adverum Biotechnologies (NASDAQ:ADVM) Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer bought 117,614 shares of the company's stock in a transaction that occurred on Monday, December 8th. The shares were...

Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 524,560 shares of Adverum Biotechnologies stock in a transaction on Thursday, December 4th...

Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 524,560 shares of the company's stock in a transaction on Thursday, December 4th. The...

Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells 222,925 Shares of Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 222,925 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The...

Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $1,260,000.00 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of the stock in a transaction that occurred on Monday, December 1st. The...

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Adverum Biotechnologies Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$4.36
Prev Close	$4.26
Open	$4.24
Dividend Yield	0.00%
50-Day Moving Average	$4.39
Beta	0.99
Avg. Volume	355,158.84
PE Ratio	-0.51

52-Week High	$5.75
52-Week Low	$1.78
Market Capitalization	$96.26M
EPS (Annual)	-$6.62
Price to Book	-1.72
Revenue Per Employee	$6,451.61
Enterprise Value/EBITDA	N/A

ADVM
Adverum Biotechnologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADVM News

ADVMAdverum Biotechnologies Inc